Robust induction of $T_{RM}$s by combinatorial nanoshells confers cross-strain sterilizing immunity against lethal influenza viruses

Pin-Hung Lin, Chieh-Yu Liang, Bing-Yu Yao, Hui-Wen Chen, Ching-Fu Pan, Li-Ling Wu, Yi-Hsuan Lin, Yu-Sung Hsu, Yu-Han Liu, Pei-Jer Chen, Che-Ming Jack Hu, and Hung-Chih Yang

Antigen-specific lung-resident memory T cells ($T_{RM}$s) constitute the first line of defense that mediates rapid protection against respiratory pathogens and inspires novel vaccine designs against infectious pandemic threats, yet effective means of inducing $T_{RM}$s, particularly via non-viral vectors, remain challenging. Here, we demonstrate safe and potent induction of lung-resident $T_{RM}$s using a biodegradable polymeric nanoshell that co-encapsulates antigenic peptides and TLR9 agonist CpG-oligodeoxynucleotide (CpG-ODN) in a virus-mimicking structure. Through subcutaneous priming and intranasal boosting, the combinatorial nanoshell vaccine elicits prominent lung-resident CD4+ and CD8+ T cells that surprisingly show better durability than live viral infections. In particular, nanoshells containing CpG-ODN and a pair of conserved class I and II major histocompatibility complex-restricted influenza nucleoprotein-derived antigenic peptides are demonstrated to induce near-sterilizing immunity against lethal infections with influenza A viruses of different strains and subtypes in mice, resulting in rapid elimination of replicating viruses. We further examine the pulmonary transport dynamic and optimal composition of the nanoshell vaccine conducive for robust $T_{RM}$ induction as well as the benefit of subcutaneous priming on $T_{RM}$ replenishment. The study presents a practical vaccination strategy for inducing protective $T_{RM}$-mediated immunity, offering a compelling platform and critical insights in the ongoing quest toward a broadly protective vaccine against universal influenza as well as other respiratory pathogens.

INTRODUCTION

Distinct from their circulatory central memory ($T_{CM}$) and effector memory T cell ($T_{EM}$) counterparts, resident memory T cells ($T_{RM}$s) have been recently identified as a specialized population of non-circulatory memory T cells that are poised to immediately respond to invading pathogens. $T_{RM}$s trigger rapid innate and adaptive immune responses by secretion of cytokines and provide first-line immune protection. In the lungs, pulmonary $T_{RM}$s possess unique homing molecules and surface markers such as CD69 and CD103 that facilitate durable residence in lung mucosa, and these cells have been proven critical for cross-protection against multiple respiratory diseases including influenza, tuberculosis, respiratory syncytial virus, and coronaviruses. While many studies conducted by infection with viral vectors have shown compelling evidence of pulmonary $T_{RM}$-mediated antiviral protection, non-viral strategies at inducing pulmonary $T_{RM}$s remain largely inadequate at achieving the sterilizing immunity attainable via live infections. As non-viral vectors, particularly those containing defined T cell peptide antigens, offer the allure of improved safety, logistics, and defined and controllable $T_{RM}$ induction, their development can help answer essential questions in $T_{RM}$ biology and provide a viable platform for $T_{RM}$ Vaccine preparation against pandemic threats.

Among respiratory infections, influenza has remained one of the most primary public health concerns that emerge seasonally, and this infectious disease has also drawn much $T_{RM}$-related vaccine research, as current influenza vaccines that induce antibodies are ineffective in coping with frequently mutated viral surface proteins, namely hemagglutinin (HA) and neuraminidase (NA), and fail to protect against distantly related strains or different subtypes. Annual reformulation of influenza vaccines is thus required to keep pace with the continuous viral evolution. In contrast to neutralizing antibody responses that are often strain specific, T cells recognizing the epitopes derived from the conserved internal viral proteins, like nucleoprotein (NP) and matrix protein 1 (M1), bear the potential to cross-protect against different influenza strains and subtypes, including emerging viral strains. Identification of highly conserved CD8+ T cell epitopes across all three influenza virus types A, B, and C as well as the higher fitness costs for viral mutation...
Figure 1. Induction of robust antigen-specific T cell responses with minimal systemic adverse effects by combinatorial nanoshell vaccines

(A) Schematic representation of a combinatorial nanoshell vaccine containing MHC class I and class II-restricted peptide antigens and CpG. (B and C) CryoEM visualizations of empty PLGA nanoshells (B) and peptide- and CpG-loaded nanoshells (C). (D) Dynamic light scattering measurement of nanoparticles loaded with OVA I/II peptides and CpG.

(legend continued on next page)
from these T cell epitopes further offer glimpses of hope that a universal T cell-based influenza vaccine may be attainable upon effective T<sub>RM</sub> priming. As recent reports highlight the continuing challenge in antibody-based vaccination strategy against mutation-prone viral strains, strategies to induce protective T cell immunity warrant major considerations in the quest for a universal influenza vaccine.25,26

In order to effectively stimulate T cell responses to peptide antigens and minimize the reactogenic effect of immunologic adjuvants, synthetic nanocarriers have emerged as a compelling non-viral approach for stimulating immune potentiation with minimal safety concerns. Recent advances in emulsion protocols and formulation control have made possible the preparation of biodegradable polymeric nanoshells with structural semblance to virus capsids allowing for efficient partitioning of water-soluble cargoes in the aqueous core and opening new opportunities for formulation designs. With the aim of examining the prospect of optimizing T cell-based influenza vaccines, we here adopted the thin-shell hollow polymeric nanoparticle, called nanoshell, to formulate influenza virus-derived T cell epitope peptides. Combinatorial nanoshells co-encapsulating CpG-oligodeoxynucleotide (CpG-ODN) and major histocompatibility complex (MHC) class I- and MHC class II-restricted antigenic peptides of influenza A virus (IAV) were prepared, and their physicochemical properties, immunogenicity, reactogenicity, and antiviral protectivity were systematically characterized.

Amid growing interest in the role of T<sub>RM</sub> cells in protection against respiratory virus infection as well as increasing reports highlighting the implication of T cell immunity in antiviral protection in the current COVID-19 pandemic, the present study further explores the influence of vaccine composition and vaccination route on the establishment of pulmonary T<sub>RM</sub>. Of great translational interest, we observe that robust induction of T<sub>RM</sub> cells in mice vaccinated with a rationally designed vaccination formulation and scheme confers full resistance to lethal IAV infections of four different strains and subtypes. The study demonstrates insights and a viable non-viral vaccination strategy toward eliciting robust and protective lung-resident T cell immunity against lethal respiratory viral infections. The finding offers new opportunities for universal influenza vaccine development and provides a versatile strategy against mutation-prone pandemic threats.

**RESULTS**

**Preparation and characterization of combinatorial nanoshell vaccines co-encapsulating peptides and CpG-ODN**

To assess T cell-mediated antiviral effect and to examine T cell dynamics via lineage tracking, we prepared vaccines containing two different pairs of class I and II MHC-restricted antigenic peptides, either NP<sub>366–374</sub> (NP<sub>I</sub> peptide)/NP<sub>311–325</sub> (NP<sub>II</sub> peptide) or OVA<sub>257–264</sub> (OVA<sub>I</sub>)/OVA<sub>323–339</sub> (OVA<sub>II</sub>). NP<sub>I</sub>/NP<sub>II</sub> peptides were derived from the authentic influenza viral NP protein; OVA<sub>II</sub> peptides from the model antigen ovalbumin (OVA) were adopted to monitor antigen-specific T cells in vivo in conjunction with clonotypic OT-I and OT-II T cells after adoptive T cell transfer. Building on our previous report that integrates CpG-ODN adjuvant (CpG) for boosting antiviral T cells, we prepared combinatorial nanoshell vaccines co-encapsulating CpG with either pair of antigenic peptides (Figure 1A). The desired encapsulant mixtures were first prepared in 200 mM sodium bicarbonate, which was subsequently used as the inner aqueous phase for nanoshell preparation. Using an optimized double emulsion protocol previously shown to readily encapsulate aqueous cargoes dissolved in the inner aqueous phase, hollow nanoparticles possessing a shell ~10 nm in thickness and a unimodal size distribution with large aqueous inner cores were consistently prepared (Figures 1B–1D). High-efficiency peptide and CpG encapsulation was confirmed with high-performance liquid chromatography (HPLC) (Figures S1A–S1C, Table S1), which showed that the solubilized peptides and CpG were readily partitioned into the virus-sized hollow nanoparticles at ~50% efficiency. Successful cargo encapsulation was also visually affirmed under cryoelectronic microscopy (cryoEM), which revealed a prominent grained texture indicative of concentrated biologic content inside an NP<sub>I</sub>/NP<sub>II</sub>/CpG nanoshell (NS(NP<sub>III</sub> + CpG)) (Figure 1C) or an OVA<sub>I</sub>/OVA<sub>III</sub>/CpG nanoshell (NS(OVA<sub>III</sub> + CpG)) (Figure S1D). The physicochemical properties of the nanoshells were largely similar for the different combinatorial encapsulants used in the present study (Table S1). Immediately after the nanoshell preparation, the nanoformulations were stored at ~20°C and thawed right before use. One milligram of the nanoparticles contains ~10 μg of OVA<sub>I</sub>/NP<sub>II</sub> peptides, 10 μg of OVA<sub>II</sub>/NP<sub>III</sub> peptides, and/or 5 μg of CpG, which corresponds to ~9,000 peptides and/or 450 CpG per nanoshell based on particle concentration measurement by nanoparticle tracking analysis (Figure S1E).

**Combinatorial nanoshell peptide vaccines with CpG induce robust antigen-specific T cell responses without systemic inflammatory effects**

To evaluate the antigen-specific CD<sub>4+</sub> and CD<sub>8+</sub> T cell responses induced by the combinatorial nanoshell peptide vaccines, we subcutaneously (s.c.) immunized C57BL/6 mice with titrated doses of nanoshells, ranging from 20 μg to 500 μg, that co-encapsulated NP<sub>I</sub>/NP<sub>II</sub> peptides and CpG (NS(NP<sub>I</sub>/NP<sub>III</sub> + CpG)). For comparison purposes, mice were immunized with NP<sub>I</sub>/NP<sub>III</sub> peptide nanoshell vaccine without

**www.moleculartherapy.org**
CpG NS(NPI/NPII) or the simple mixture (no nanoshell carrier) of NP/PEP or NP/PEP and CpG (NP/PEP + CpG) either in a lower dose (5 µg/5 µg NP/PEP peptides and 2.5 µg CpG) equivalent to that in 500 µg of NS(NPI/NPII) + CpG) or in a higher dose (10 µg/10 µg NP/PEP peptides and 50 µg CpG) that was a minimal peptide/adjuvant content required for T cell stimulation as assessed in our prior study. On day 7 after immunization, analysis of cells in the spleens and inguinal draining lymph nodes (dLNs) of vaccinated mice by flow cytometry showed that NS(NPI/NPII + CpG) induced robust interferon (IFN)-γ production in a dose-dependent manner. Moreover, 500 µg of NS(NPI/NPII + CpG) induced significantly higher IFN-γ production than 500 µg of NS(NPI/NPIII) and the simple mixture NP/PEP + CpG in both doses, highlighting the enhanced immunogenicity by CpG and nanoshell formulation (Figure 1E). The immunogenicity of NS(OVAP I + CpG) was assessed in Thy1.2+/c mice adoptively transferred with carboxyfluorescein succinimidyl ester (CFSE)-stained Thy1.1+/c OT-I and Thy1.1/Thy1.2 OT-II T cells (Figure S2A). Similarly, we observed that NS(OVA I + CpG) induced prominent levels of proliferating and IFN-γ-producing CD4+ OT-II T cells in both spleens and dLNs and IFN-γ-producing CD8+ OT-I T cells in spleens (Figures S2B–S2E). Notably, no obvious weight loss was observed in all nanoshell-vaccinated mice, whereas significant weight loss was observed in mice administered the simple mixture OVA I + CpG (Figure 1F). Furthermore, nanoshell encapsulation was also shown to minimize the effect of spleen enlargement by CpG (Figures 1G and 1H). These results demonstrate that the nanoshell-peptide vaccine with CpG exhibits excellent immunogenicity and allows for significant adjuvant dose sparing and reduction in undesirable reactogenicity for antiviral T cell priming.

Combinatorial nanoshell vaccines elicit near-sterilizing cross-protective T cell immunity against lethal IAV infection

Next, we assessed the antiviral protective efficacy of the combinatorial nanoshell vaccine peptides against influenza virus infection. We chose 500 µg of combinatorial nanoshell vaccines for the ensuing experiments because it exhibited the highest immunogenicity and negligible systemic reactogenicity. With the aim of inducing TregS for effective antiviral protection, we implemented the peripheral-prime-local-boost (s.c./intranasal) strategy with a 28-day interval between priming and boosting (Figure 2A). Our preliminary result also showed that i.n. priming by nanoshell vaccine with combined MHC-I and MHC-II epitope peptides NS(NP I + CpG) induced significantly higher protective T cell immunity against influenza virus infection than priming by either MHC-I epitope NS(NP I + CpG) or MHC-II epitope NS(NPII + CpG) alone (Figure S3). Thus, through this s.c./i.n. prime-boost strategy, we compared the protective efficacy of NS(NPI + CpG) against a lethal dose of influenza PR8 strain with other control vaccine formulations, including empty nanoshell, NP I peptides alone, simple mixture of NP I plus CpG, and NS(NPIII). In a stark contrast to control formulations and to the subdued protective effect typically exhibited by T cell peptide vaccines against influenza,18,39 we observed that immunization with s.c./i.n. NS(NPII + CpG) fully protected mice against the PR8 infection, with all the mice surviving and recovering with minimal body weight loss (Figures 2B and 2C). None of the control formulations, on the other hand, showed improvement in morbidity and mortality in the challenged mice. Very strikingly, the mice immunized with NS(NPII + CpG) exhibited undetectable viral loads on day 7 post infection, whereas all other groups showed high viral loads in lungs (>10⁷ plaque-forming units [PFU] per lung) (Figure 2D). Viral kinetics analysis revealed rapid and profound suppression of replicating viruses in the lungs of mice receiving s.c./i.n. NS(NPII + CpG), but the viral lung loads of the control mice vaccinated by empty nanoshells remained largely steady through day 7 post infection (Figure 2E). We also found that immunization with s.c./i.n. NS(NPII + CpG) resulted in the highest IFN-γ-producing NP I-specific CD8+ and CD4+ T cells in lungs (Figure 2F) and in dLNs and spleens as well at 7 days post PR8 infection (Figure S4).

Given the promising protective efficacy of NS(NPII + CpG) against PR8, we further examined the vaccine’s protective effect against different viral strains and subtypes. The antigenic peptides NP I and NP III are conserved among a number of IAV strains, including PR8 (H1N1), WSN (H1N1), HKx31 (H3N2), and VNHA/NA (H5N2). Of note, both HKx31 and VN HA/NA are recombinant influenza viruses with identical internal genes derived from the PR8 but with surface HA and NA proteins from A/Aichi/2/68 (H3N2) and A/Vietnam/1203/04 (H5N1), respectively.40 Mice receiving s.c./i.n. NS(NPII + CpG) vaccination also exhibited 100% survival after lethal challenges with WSN, HKx31, or VNHA/NA and had undetectable viral loads on day 7 post infection (Figures 2G–2I), whereas all mice immunized by empty nanoshells died by day 8. These results highlight the feasibility of T cell-based antiviral peptide vaccine with broadly neutralizing potential using the nanoshell platform.

Figure 2. The immunogenicity and protective efficacy of combinatorial nanoshells with NPA65-73/CpG or NPA65-73/CpG

(A) Schematic illustration of vaccination strategy with NS(NPI + CpG) to induce protective T cell immunity against heterosubtypic IAV infection. Mice were immunized by s.c. priming (500 µg/mouse) and i.n. boosting (300 µg/mouse) with the indicated vaccine formulations and then infected by different strains of influenza virus (PR8, WSN, HKx31, and VNHA/NA [H5N1]). (B and C) The body weight (B) and survival rates (C) of PR8-infected (110 PFU) mice immunized by indicated vaccine formulas. A body weight reduction of 25% or more was defined as the experimental end point, and mice were then euthanized at day 7 post infection. (D) Lung viral loads of mice immunized by different vaccine formulations were analyzed at day 7 post PR8 infection (n ≥ 4 mice per group compiled from 2 independent experiments). (E and F) The viral kinetics (E) and T cell immunity (F) of nanoshell vaccine-immunized mice after challenge by lethal PR8 infection. (F) Individual percentages with means plus SE of NP I-specific and NP II-specific IFN-γ-producing CD8+ and CD4+ T cells, respectively, in lungs at day 7 post-PR8 infection (n ≥ 5 mice per group compiled from 2 independent experiments). (G–I) Mice were immunized by s.c. priming and i.n. boosting with the either empty nanoshells or NS(NPI + CpG) and then infected by lethal doses of WSN (1 × 10⁶ PFU/mouse) (G), HKx31 (1 × 10⁶ PFU/mouse) (H), or VNHA/NA (H5N1) (400 PFU/mouse) (I) following the experimental protocol shown in (A). Survival rates (top), body weight loss (middle), and lung viral loads (bottom) were analyzed at day 7 post infection of WSN (G), HKx31 (H), and VNHA/NA (H5N1) (I) (n ≥ 5 mice per group compiled from 2 independent experiments). *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001, ****p ≤ 0.0001 (Fisher’s exact test for survival rate, Student’s t test for viral kinetics, and one-way ANOVA for lung viral load and percentages of IFN-γ production).
Figure 3. Uptake and tracking of nanoshell vaccines in lungs and dLNs

(A) The percentages of macrophages (SSC<sup>high</sup>CD11c<sup>+</sup>MHC-II<sup>low</sup>F4/80<sup>+</sup>) and DCs (SSC<sup>low</sup>CD11c<sup>+</sup>MHC-II<sup>high</sup>CD103<sup>+</sup> and SSC<sup>low</sup>CD11c<sup>+</sup>MHC-II<sup>high</sup>CD11b<sup>+</sup>) in lungs at 12 h, 24 h, and 48 h after i.n. administration of nanoparticles (n = 4 mice per group compiled from 2 independent experiments).

(B) t-distributed stochastic neighbor (continues on next page)
Efficient uptake and transport of combinatorial nanoshell vaccines by CD11c-positive dendritic cells (DCs)

Intrigued by the prominent T cell activation and antiviral protectivity by the nanoshell vaccines, we further explored their cellular uptake and pulmonary transport in vivo by incorporating a water-soluble tracking dye, Alexa Fluor 555 (AF555). For ease of T cell tracking by lineage marker in subsequent studies, nanoshell vaccines incorporating OT-I and OT-II peptides (OVA1/II) were adopted from this point onward. Subcutaneously administered nanoshells readily drained to the dLNs, as is the case typically observed with delivery carriers of similar dimensions (Figure S5). As the pulmonary transport of nanocarriers is less commonly studied, we further explored the fate of the nanoshells upon i.n. administration, after which the cellular uptake of nanoshells was determined by analysis of fluorescent cells isolated from the lungs and dLNs at 12, 24, and 48 h post immunization. We found that in the lungs, nanoshells were taken by a significant portion of SSChighCD11cF4/80+ macrophages and SSClowCD11c+ conventional DCs (cDCs), including CD103+CD11b− and CD103−CD11b+ cDCs (Figures S6A and S6B). Uptake of nanoshells by macrophages and DCs peaked at 24 h post immunization, and, notably, CpG adjuvant significantly increased the uptake of nanoshells by CD103−CD11b+ cDCs (29.0% versus 46.4%, p < 0.01) and CD103+CD11b− cDCs (51.0% versus 65.3%, p < 0.05) but not by macrophages (78.3% versus 82.8%, p > 0.05) (Figure 3A). We then measured the expression of CD86, an activation and maturation marker of DCs, in nanoshell-loaded DCs (AF555+ DCs). We found that CpG adjuvant enhanced the expression of CD86 in CD103−CD11b+ cDCs at 24 h post immunization and in CD103+CD11b− cDCs at 24 and 48 h post immunization (Figures 3B and 3C). Upon tracking the nanoshell-loaded (AF555+) cells in the dLNs, only AF555+CD11c+ DCs could be observed and no AF555+ F4/80+ macrophages were found. In addition, CD11c+ DCs of dLNs in mice immunized by NS(OVA1/II + CpG + AF555) had significantly higher green fluorescence intensity of CD86 than those in mice immunized by NS(OVA1/II + CpG), whereas CD11c− cells exhibited low green fluorescence intensity (Figures 3D and 3E). Collectively, the data show that a high proportion of macrophages and DCs effectively took nanoshells in the lungs, but only CD11c+ DCs migrated to the dLNs. Furthermore, CpG enhanced the uptake of nanoshells and maturation of DCs.

CD11c+ DCs are critical for activation of T cells by combinatorial nanoshell vaccines

To validate the role of CD11c+ DCs in stimulating antigen-specific T cells by the combinatorial nanoshell vaccines in lungs, we utilized CD11c-DTR mice, in which CD11c+ cells, primarily DCs and some macrophages, can be specifically depleted by addition of diphtheria toxin (DT). Naive Thy1.2+/+ CD11c-DTR mice were treated with DT once via intraperitoneal (i.p.) administration and then adoptively transferred with CFSE-stained Thy1.1+/+ OT-I and Thy1.1/Thy1.2 OT-II T cells on the next day. Subsequently, mice were i.n. instilled with NS(OVA1/II + CpG) and sacrificed for analysis 3 days later (Figure 4A). We observed that DT treatment resulted in significant reduction of CD11c+ cells in the lungs and the dLNs (Figure 4B; Figure S7A). Depletion of CD11c+ cells dramatically attenuated the prolife-ration of antigen-specific CD4+ OT-II and CD8+ OT-I T cells (Figure 4C; Figure S6B) and caused a 2-log decrease of their cell numbers (Figure 4D). Taken together, the results indicate that CD11c+ DCs were the main antigen-presenting cells (APCs) responsible for activating antigen-specific T cells by the combinatorial nanoshell vaccines and echo recent efforts in vaccination modification strategies specifically tailored to facilitate CD11c+ DC-mediated T cell induction.41,42

Elicitation of robust lung-resident and circulatory memory T cells by the peripheral-prime-local-boost vaccination strategy

T RM cells in lungs are essential for the first-line defense against respiratory viral infections, and vaccine administration through the i.n. route is considered critical to generation of tissue-resident memory T cells. However, several studies have reported that T RM replenishment is mediated by T EMs, which is most effectively stimulated via parenteral vaccination.43 Intrigued by the influence of and with the aim of optimizing vaccination routes for T RM induction, we set out to enumerate epitope-specific T RM cells in vivo, following different vaccination schemes with the nanoshell vaccine. We first compared the protective efficacy of NS(OVA1/II + CpG) vaccine primed and boosted via s.c./i.n., i.n./i.n., or s.c./s.c. vaccination routes in wild-type (WT) mice in the absence of adoptive transfer. Four weeks after boosting, mice were challenged by i.n. instillation with a lethal dose of HKx31-OVA1/II (Figure 5A). Mice that were immunized with NS(OVA1/II + CpG) by s.c. priming and i.n. boosting exhibited less weight loss (Figure 5B) and the best survival outcome, with no observed mortality (Figure 5C), and mice receiving i.n./i.n. priming and boosting with NS(OVA1/II + CpG) had the second-best survival outcome. Notably, despite the high immunogenicity of the NS(OVA1/II + CpG), s.c./s.c. immunization conferred very limited antiviral protective efficacy. Consistent with their improved mortality and morbidity, the s.c./i.n. and i.n./i.n. NS(OVA1/II + CpG) groups had the lowest lung viral loads upon examination at day 5 post infection (Figure 5D). In addition, mice in the s.c./i.n. NS(OVA1/II + CpG) group showed the strongest CD8+ and CD4+ T cell responses in both spleens and mediastial dLNs at day 5 post infection (Figure 5E). Collectively,
the results demonstrate that the local (i.n.) boosting strategy is critical for the induction of protective T cell immunity against IAV infection.

As both s.c./i.n. and i.n./i.n. immunizations with combinatorial nano-shell vaccines conferred more effective antiviral immunity compared with the s.c./s.c. vaccination strategy, we further investigated how peripheral-prime-local-boost strategy may influence the circulatory and lung-resident T cell populations. To measure the antigen-specific memory T cells, naive Thy1.1+OT-I CD8+ T cells isolated from splenocytes were adoptively transferred to WT Thy1.2+ C57BL/6 mice, which were subsequently immunized by i.n./i.n. NS(OVA I/II + CpG) or s.c./i.n. NS(OVA I/II + CpG). One month after boosting, sub-populations of memory T cells, including TCMs, TEMs, and TRMs, were analyzed by flow cytometry (Figure 6A). Based on the expression of KLRG and CD62L, TCM cells were defined as KLRGlowCD62high and TEM cells were KLRGhighCD62Llow (Figure S8A), and TRM cells were determined by in vivo staining through the expression of CD69 or CD103 (Figure S8B). Our analysis showed that although the two groups had similar numbers of OT-I TRM cells in lungs, mice that were immunized via the s.c./i.n. route generated significantly more TEM and TCM cells in the spleens than mice with i.n./i.n. vaccination (Figure 6B). We further examined the influence of elevated circulatory T cell response on TRM dynamics by depleting lung-resident CD8+ T cells via intratracheal (i.t.) administration of anti-CD8 antibody, based on a protocol that can solely deplete lung-resident CD8+ T cells without affecting circulatory CD8+ T cells.45 Our pilot experiment showed that this protocol could deplete >90% lung-resident CD8+ T cells effectively without significantly affecting the circulatory CD8+ T cells (data not shown). Seven days post CD8+ TRM depletion on day 28 after vaccine boosting, mice receiving the s.c./i.n. immunization showed similar numbers of TEM cells in spleens compared with those receiving i.n./i.n. immunization following TRM depletion (Figure 6C). The more efficient TRM recovery as well as the larger TEM differential observed for the s.c./i.n. group in the depletion study strengthens the correlation between TEM levels and their conversion to TRM cells. Collectively, although i.n./i.n. and s.c./i.n. immunizations induced similar levels of TRM cells in the lungs 1 month after booster vaccination, the enhanced antiviral protectivity, elevated circulatory TEM cell population, and better TRM replenishment in lungs support s.c./i.n. prime-boost as a superior vaccination strategy.

**Figure 4. T cell proliferation stimulated by combinatorial nanoshell vaccine after depletion of CD11c-positive DCs**

(A) Schematic representation of the experimental protocol. CD11c-DTR mice received PBS or DT depletion once. On the next day mice were co-transferred with CFSE-stained Thy1.1+CD8+OT-I and Thy1.1/Thy1.2 CD4+OT-II cells and then i.n. immunized with NS(OVA I/II + CpG). (B) The fold change of CD11c+ cells in immunized mice at day 5 post PBS or DT treatment. (C and D) Individual percentages (C) and cell numbers (D) of proliferating CD4+OT-II and CD8+OT-I cells in dLNs in immunized mice at day 5 post PBS or DT treatment. (n ≥ 6 mice per group compiled from 3 experiments). **p ≤ 0.01; ***p ≤ 0.001 (Student’s t test).
DISCUSSION

Non-viral vector peptide vaccines intended to elicit T cell immunity against viral infections have generally generated disappointing levels of protection,\(^8^{25,26}\) and, to the best of our knowledge, an effective T cell peptide vaccine capable of conferring potent cross-strain influenza protection has not been previously reported. In this study, we demonstrated that a combinatorial nanoshell vaccine co-encapsulating a single pair of class I and class II MHC-restricted epitope peptides and CpG, when given by peripheral s.c. priming and local i.n. boosting, was able to induce near-sterilizing antigen-specific lung-resident and circulatory T cell immunity, which in turn conferred cross-protection against lethal IAVs of different strains (PR8, WSN, HKx31, and VN\(^{HA/NA}\)) and subtypes (H1N1, H3N2, and H5N1). Mice immunized by nanoshells with NP\(_{366–374}\)/NP\(_{311–320}\) suppressed viral replication by \(\sim 1,000\)-fold at day 5 and reduced lung viral loads to undetectable levels by day 7 post infection (>100,000-fold less). The vaccination strategy that elicits protective T cell immunity against IAV infection is summarized and depicted in Figure 7, and both magnitude and location of antigen-specific T cells were found to be critical to antiviral protectivity. The study demonstrates the viability of peptide-based T cell vaccines for cross-reactive influenza protection, highlighting key insights in formulation design, delivery strategy, vaccination routes, and mechanistic basis for optimizing T cell immunity against IAV infections.

Poly(DL-lactide-co-glycolide) (PLGA) is a commonly used biomaterial for vaccine development owing to its biocompatibility and synthetic flexibility.\(^46^{49}\) To maximize antiviral T cell immunity, T cell epitope peptides and adjuvants were co-encapsulated in PLGA-based hollow nanostructures with an average diameter of 160 nm, yielding vaccine particles with close structural semblance to natural virions. The particle formulation allows for modular antigen and adjuvant incorporation with consistent encapsulation efficiencies, and the ability to adjust nanoshell composition enables interrogation of the T\(_{RM}\) induction mechanism. We showed that both antigen and adjuvant were conducive to T\(_{RM}\) establishment during i.n. boosting, and through tracking with fluorescent dye-loaded nanoshells, their pulmonary transport dynamic was further elucidated. The nanoshells were efficiently taken up by CD11c\(^+\) macrophages and DCs, and nanoshell-associated CD11c\(^+\)CD103\(^+\) and CD11c\(^+\)CD11b\(^+\) DCs were readily identified in the dLNs. This transport pattern is strikingly similar to that of viral particles following pulmonary infections and informs design considerations for T\(_{RM}\)-inducing delivery vehicles.\(^20^{25,26}\) We also observed that specific depletion of CD11c\(^+\) cells by DT dramatically reduced the proliferation of T cells stimulated by nanoshell vaccines, supporting that CD11c\(^+\) DCs were responsible for the priming activity of the nanoshell vaccines in lungs.\(^32^{35}\) It is noteworthy to point out that even though empty nanoshells and CpG-loaded nanoshells share similar physicochemical properties, incorporation of CpG was observed to increase DC uptake. With incorporation of DC-targeting ligands frequently employed to enhance vaccine potency,\(^41^{42}\) this finding highlights that the inherent immunogenicity of nanoparticles can be tuned to favor their cellular distributions to DCs.

With the quantity and persistence of pulmonary T\(_{RM}\) cells being critical factors that can influence antiviral protectivity,\(^42^{56}\) the vaccination route is among the many important factors toward optimizing T\(_{RM}\) establishment.\(^25^{27}\) We assessed several immunization strategies and demonstrated that local boosting was critical for the establishment of robust T\(_{RM}\) and protectivity against IAV. By comparing i.n./i.n. and s.c./i.n. prime-boost vaccinations, we observed a correlation between the heightened T\(_{EM}\) levels in the s.c./i.n. group and improved pulmonary T\(_{RM}\) replenishment and antiviral protectivity. This finding is critical for development of vaccination regimens for reliable antiviral protectivity,\(^5\) and it also echoes reports that highlight circulatory T\(_{EM}\) cells and parenteral immunization as major factors promoting pulmonary T\(_{RM}\) durability and replenishment.\(^32^{35}\) As the dynamics and factors for T\(_{RM}\) establishment remain ongoing topics of investigation, future studies with additional nanoshell compositions are warranted.

The prominent antiviral efficacy against lethal influenza challenge observed in the present work is highly encouraging and opens up the exciting prospect of nanoshell-based T\(_{RM}\) vaccine for broadly neutralizing influenza vaccination as well as for other respiratory infections. Antigenic peptide also holds several advantages over recombinant protein for its vastly easier synthesis process and convenient scalability to effectively cope with emerging and re-emerging infectious diseases. To realize the vision of clinical translation, identification of influenza epitope peptides presented by common human leukocyte antigen alleles is required to achieve wide population coverage. Such efforts can be facilitated by the advances in modern technology for T cell epitope identification, including the use of epitope prediction algorithms and mass spectroscopy immunopeptidomics.\(^39^{60}\) Encouragingly, highly conserved CD8\(^+\) T cell epitope
peptides across influenza A, B, and C viruses have been identified, lending plausibility to T cell-based universal influenza vaccination. Of note, a high level of cross-reactivity between severe acute respiratory syndrome (SARS)-NP induced T cells and SARS coronavirus 2-NP has also been reported, suggesting the feasibility of a pan-coronavirus vaccine based on TRM induction against conserved T cell epitopes. The combinatorial polymeric nanoshell provides a versatile platform that can be iteratively optimized to maximize epitope coverage and immune stimulation. It is also anticipated to bridge the gap between the exciting frontier of TRM research and its practical utility in disease prevention.

**MATERIALS AND METHODS**

**Mice**

All mouse experiment protocols were approved by the Laboratory Animal Committee of National Taiwan University College of Medicine. C57BL/6 (B6) WT mice came from the National Laboratory Animal Center in Taiwan. The breeder pairs of Foxp3gfp were a gift from Dr. Alexander Rudensky (New York, NY, USA). CD11c-DTR mice were a gift from Dr. Ping-Ning Hsu (National Taiwan University) and were maintained in the National Laboratory Animal Center in Taiwan. Thy1.1 × OT-I and Thy1.1/Thy1.2 × Foxp3gfp × OT-II mice were generated by cross-breeding the indicated mouse lines in...
Viruses, infection, and virus quantification

The plasmids hemagglutinin (HA) and neuraminidase (NA) of HKx31 cloned in pHW2000 were a gift from Dr. Paul Thomas (Memphis, TN, USA). WSN was a gift from Chi-Ju Chen (National Yang-Ming University, Taiwan). The VNHA,NA virus was kindly provided by Richard Webby, with its multibasic HA cleavage site replaced by that of a low-pathogenicity avian influenza virus. The HKx31-HA-OVAI/II was generated by a strategy described previously. Briefly, we first modified the OVA OT-I/OT-II peptide (OVA257–264/OVA323–339) by adding SR (XbaI site), GT (KpnI site), and GGGGS linker to generate SR-SIINFEKL/ISQAVHAAHAEINEAGRGT-GGGGS and then inserted the sequence into HKx31-HA after the glycine at residue 17. All viruses, including HKx31-HA-OVAI/II, PR8, HKx31, and WSN, were produced by the 8-plasmid reverse genetics system and propagated in Madin-Darby canine kidney (MDCK) cell monolayers, and the titers were determined by the plaque assay. Six- to eight-week-old mice were fully anesthetized by i.p. injection of Rompun (xylazine) and Zoletil (tiletamine hydrochloride and zolazepam hydrochloride) and then infected with 20 µL of viral suspension with indicated doses of viruses via the i.n. route.

For measuring the survival rate of mice infected by influenza virus, mice were humanely euthanized when they reached 25%–30% loss of their initial body weight. For measurement of lung viral titer of infected mice, lungs were isolated and homogenized in 1 mL of infection medium consisting of DMEM with non-essential amino acids solution (NEAA), sodium pyruvate, and bovine serum albumin. Lung viral loads were determined by inoculation of MDCK cells with serial 10-fold dilutions of the lung suspension with the plaque assay.

Preparation of combinatorial nanoparticle vaccines

Combinatorial nanoparticle vaccines were prepared by a water-in-oil-in-water double emulsion process adapted from a previously reported method. A polymer solution was prepared by dissolving 50 mg/mL of carboxy-terminated, 50:50 PLGA (0.15–0.25 dL/g, corresponding to ~10,000 Da; LACTEL Absorbable Polymers) in dichloromethane. The inner aqueous phase was prepared by dissolving the desired peptide mixtures, CpG-ODN 1826 (InvivoGen), and/or Alexa Fluor 555 Cadaverine dye (Sigma-Aldrich) in 200 mM sodium bicarbonate solution to enhance peptide and CpG-ODN solubility. For the different combinatorial nanoparticles, the inner aqueous phases contained 10 µg/mL of each designated peptide (i.e., OVA257–264 [OVAI peptide] /SIINFEKL/, OVA323–339 [OVAII peptide] /ISQAVHAAHAEINEAGR/, NP366–374 [NPi peptide] /ASNENMETM/, and NP311–325...
Quantification of peptide and CpG-ODN loading by HPLC analysis

Trifluoroacetic acid (TFA) was purchased from Alfa Aesar (Heysham, UK). Acetonitrile was purchased from J.T. Baker (Avantor Performance Materials, Center Valley, PA, USA). Glacial acetic acid was purchased from Macron Fine Chemicals (Avantor Performance Materials, Center Valley, PA, USA). Triethylamine was purchased from Sigma-Aldrich (St. Louis, MO, USA). All reagents and chemicals were analytical grade. The HPLC analysis was carried out in an Agilent Technologies Series 1100 apparatus (Waldbronn, Germany). The analytical column was an Ascentis Express C18 reverse-phase column (Supelco). The column temperature was kept at 25°C during the quantification. For peptide antigen quantification, the mobile phase consisted of phase A (0.1% TFA in acetonitrile) and phase B (0.1% TFA in water). The samples were run with a linear gradient elution from 10% to 95% of phase A over 15 min and then kept constant at 95% phase A for 5 min. Then, the eluent was reversed to the initial composition within 5 min. The wavelength of detection was set at 210 nm for OVAI and OVAII peptides, and the flow rate was set at 1.0 mL/min. NP4 and NP14 peptides were measured at 215 nm and with a flow rate of 0.75 mL/min. For CpG-ODN quantification, the mobile phase consisted of 5.70 mL of glacial acetic acid and 13.90 mL of triethylamine mixed with Milli-Q water, which yielded a 0.1 M triethylammonium acetate buffer. The pH was adjusted to 7. The mobile phase B was acetonitrile. The mobile phases A and B were run at a 50:50 volume ratio during elution. CpG-ODN was measured at 260 nm and with a flow rate of 0.7 mL/min.

Reagents, cell staining, and flow cytometry analysis

Cells were washed twice with staining buffer (PBS containing 2% fetal bovine serum [FBS]) and stained with fluorescence-conjugated antibodies against surface markers wherever appropriate, including anti-Thy1.1 BV510 clone OX-7 (BioLegend), anti-CD4 PerCP-Cy5.5 clone RM4-5 (eBioscience), anti-CD8α PE-Cy7 clone 53-6.7 (eBioscience), anti-CD44 BV650 clone IM7 (BioLegend), anti-CD69 PE clone H1.2F3 (eBioscience), anti-CD103 BV421 clone 2E7 (BioLegend), anti-CD62L BV737 clone ME-L-14 (BD Biosciences), anti-KLRG-1 BV395 clone 2F1 (BD Biosciences), anti-CD11c BB515 clone N418 (BD Biosciences), anti-CD11b BV711 clone M1/70 (BD Biosciences), anti-MHC-II, anti-CD86, anti-CD103, and anti-F4/80 for 30 min. For intracellular IFN-γ staining, cells were fixed and permeabilized (Foxp3/Transcription Factor Fixation/Permeabilization Concentrate and Diluent, eBioscience) after surface staining and then stained intracellularly with anti-IFN-γ-APC (BD Biosciences). Cells were analyzed with a fluorescence-activated cell sorting (FACS) LSRFortessa flow cytometer (BD Biosciences).

Adaptive transfer of naive OT-I and OT-II T cells

Splenocytes from indicated donor mice were prepared as a single-cell suspension and FACS sorted for CD8+ OT-I cells and CD4+OT-II+CD25+ GFP+ cells, which were adjusted to an appropriate final volume with sterile serum-free RPMI 1640 (Gibco). Each mouse received 0.3 mL of cell suspension with the OT-I cell number of 0.8 × 10^6 cells and OT-II cell number of 3 × 10^6 cells. Donor cells were transferred into recipient mice by intravenous (i.v.) injection through the tail veins.

Isolation of DCs from the lung and lymph node

NS (OVA\textsubscript{14} + AF555)- or NS (OVA\textsubscript{14} + CpG + AF555)-treated mice were sacrificed and received systemic PBS perfusion to exclude red blood cells (RBCs), and lung or dLN samples were homogenized by scissors into 1 mm\textsuperscript{2} sections. Samples were then treated with digestion buffer (0.5 mg/mL collagenase type IV, 25 U/mL type IV DNase I in RPMI 1640 supplemented with 1% glutamine-penicillin-streptomycin) at 37°C for 30 min. Afterward, the reaction was stopped by addition of RPMI 1640 supplemented with 10% FBS and 1% glutamine-penicillin-streptomycin. Further, lung and LN samples were treated to single cell by 18G needle and 1 mL pipette tips, respectively. Cells were treated with RBC lysis buffer (eBioscience) and washed twice with staining buffer (PBS containing 2% FBS) for further staining.

Depletion of CD11c cells and measurement of T cell stimulation in CD11c-DTR mice

CD11c-DTR mice were treated once with i.p. DT (4 ng/g) (Calbiochem) to deplete CD11c\textsuperscript{+} cells and on the next day were transferred with 1 × 10^6 CFSE\textsuperscript{+} OT-I cells and 3 × 10^6 CFSE\textsuperscript{+} OT-II cells isolated from Thy1.1-OT-I and Thy1.1/Thy1.2/Foxp3\textsuperscript{+/-} OT-II mice, respectively. One day later, mice were immunized with NS(OVA\textsubscript{14} + CpG) through the i.n. route and analyzed for CD11c\textsuperscript{+} cell population and the proliferation of donor OT-I and OT-II cells in spleens, lymph nodes, or lungs at day 3 post immunization.

Measurement of antigen-specific T cells

To analyze the level of OVA\textsubscript{14} or NP\textsubscript{14}-specific T cells after influenza virus infection, 2–5 × 10^6 primary cells from spleens, lymph
nodes, or lungs were resuspended in 200 μL of T cell culture medium containing OVA257–264 (20 μg/mL)/OVA323–339 (40 μg/mL) peptide or NP366–374 (10 μg/mL)/NP311–325 (40 μg/mL) peptide, interleukin (IL)-2 (2 ng/mL), and GolgiPlug (BD Biosciences). Cells were incubated at 37°C for 6 h and analyzed by intracellular IFN-γ staining.

In vivo staining of lung-resident T cells
Mice were injected intravenously with 3 μg of APC-conjugated anti-CD3 Ab clone 145-2C11 (eBioscience). After 10 min, mice were sacrificed and received systemic PBS perfusion to exclude RBCs, and lung samples were digested by collagenase. Afterward, cells were treated with RBC lysis buffer (eBioscience) and washed twice with staining buffer (PBS containing 2% FBS) for further staining.

In vivo lung depletion of CD8 T cells
Mice were given two shots of 60 μg of anti-CD8 Ab (53-6.7, Bio X Cell) per mouse by i.t. injection.

Statistical analyses
Data are expressed as mean ± standard error (SE) values. The survival rates were analyzed by the log-rank test and Fisher’s exact test. Continuous variables, including lung viral titers and percentage and numbers of antigen-specific T cells, DCs, and macrophages, were analyzed by the Student’s t test or one-way ANOVA test followed by Tukey’s multiple comparison test. A p value <0.05 was considered statistically significant.

Data and materials availability
All data associated with this study are present in the paper or the Supplemental information.

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.omtm.2021.03.010.

ACKNOWLEDGMENTS
We acknowledge the service provided by the Flow Cytometric Analyzing and Sorting Core of the First Core Laboratory and the Third Core Laboratory, National Taiwan University College of Medicine. This work was supported by grants from the National Taiwan University College of Medicine and Ministry of Science and Technology, Taiwan (MOST105-2628-B-002-027-MY3 to H.-C.Y., MOST107-2321-B-002-024 to H.-C.Y. and C.-M.J.H., and MOST107-2119-M-001-042 to C.-M.J.H.).

AUTHOR CONTRIBUTIONS
P.-H.L., H.-W.C., P.-J.C., C.-M.J.H., and H.-C.Y. formed the original concepts and designs of the experiments; B.-Y.Y. and C.-M.J.H. generated polymeric nanoshells; P.-H.L. and C.-Y.L. performed the experiments and C.-F.P., Y.-H.L., and Y.-S.H. helped with tissue collection; Y.-H.L. performed the HPLC experiments; L.-L.W helped with t-SNE data analysis; P.-H.L. and C.-Y.L. acquired and interpreted data; P.-J.C., C.-M.J.H., and H.-C.Y. reviewed and helped interpret the data; P.-H.L., C.-M.J.H., and H.-C.Y. drafted and finalized the submitted manuscript.

DECLARATION OF INTERESTS
The authors declare no competing interests.

REFERENCES
1. Shenkel, J.M., and Masopust, D. (2014). Tissue-resident memory T cells. Immunity 41, 886–897.
2. Mueller, S.N., and Mackay, L.K. (2016). Tissue-resident memory T cells: local specialists in immune defense. Nat. Rev. Immunol. 16, 79–89.
3. Shenkel, J.M., Fraser, K.A., Beura, L.K., Pauken, K.E., Vezys, Y., and Masopust, D. (2014). T cell memory. Resident memory CD8 T cells trigger protective innate and adaptive immune responses. Science 346, 98–101.
4. Wu, T., Hu, T., Lee, Y.T., Bouchard, K.R., Benechet, A., Khanna, K., and Cauley, L.S. (2014). Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection. J. Leukoc. Biol. 95, 215–224.
5. Zens, K.D., Chen, J.K., and Farber, D.L. (2016). Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection. JCI Insight 1, 8582.
6. Pizzolla, A., Nguyen, T.H.O., Smith, J.M., Brooks, A.G., Kedzierska, K., Heath, W.R., Reading, P.C., and Wakim, L.M. (2017). Resident memory CD8 T cells in the upper respiratory tract prevent pulmonary influenza virus infection. Sci. Immunol. 2, eaam6970.
7. Beverley, P.C., Sridhar, S., Lalvani, A., and Tchilian, E.Z. (2014). Harnessing local and systemic immunity for vaccines against tuberculosis. Mucosal Immunol. 7, 20–26, https://doi.org/10.1038/mi.2013.99.
8. Kinnear, E., Lambert, L., McDonald, J.U., Cheeseman, H.M., Caproni, L.J., and Tregoning, J.S. (2018). Airway T cells protect against RSV infection in the absence of antibody. Mucosal Immunol. 11, 249–256.
9. Lipsitch, M., Grad, Y.H., Sette, A., and Crotty, S. (2020). Cross-reactive memory T cells and herd immunity to SARS-CoV-2. Nat. Rev. Immunol. 20, 709–713.
10. de Vries, R.D., and Rimmelzwaan, G.F. (2016). Viral vector-based lung tissue-resident memory T cells attenuate the antiviral immunity against acute influenza virus infection. Mucosal Immunol. 11, 1239–1253.
11. Knight, F.C., Gilchuk, P., Kumar, A., Becker, K.W., Sevimli, S., Jacobson, M.E., Lambkin-Williams, R., Palese, P., Shaw, M.L., Treanor, J., Webster, R.G., and García-Sastre, A. (2016). Viral vector-based in vivo mucosal and systemic immunity for vaccines against tuberculosis. Mucosal Immunol. 9, 886–897.
12. Wang, Z., Wan, Y., Qiu, C., Quiñones-Parra, S., Zhu, Z., Loh, L., Tian, D., Ren, Y., Hu, Y., Zhang, X., et al. (2015). Recovery from severe H7N9 disease is associated with a diverse response mechanisms dominated by CD8+ T cells. Nat. Commun. 6, 6883.
19. Koutsakos, M., Illing, P.T., Nguyen, T.H.O., Mifsud, N.A., Crawford, J.C., Rizzetto, S., Eltabia, A.A., Clemens, E.B., Sant, S., Clua, B.Y., et al. (2019). Human CD8+ T cell cross-reactivity across influenza A, B and C viruses. Nat. Immunol. 20, 613–625.
20. Eickhoff, C.S., Terry, F.E., Peng, L., Meza, K.A., Sakala, I.G., Van Aartsen, D., Moise, L., Martin, W.D., Schriever, J., Buller, R.M., et al. (2019). Highly conserved influenza T cell epitopes induce broadly protective immunity. Vaccine 37, 5371–5381.
21. Li, Z.T., Zarnitsyna, V.I., Lowen, A.C., Weissman, D., Koelle, K., Kohlmeier, J.E., and Antia, R. (2019). Why Are CD8 T Cell Epitopes of Human Influenza A Virus Conserved? J. Virol. 93, e01534–18.
22. Berkhoff, E.G., de Wit, E., Geelhoed-Mieras, M.M., Boon, A.C., Symons, J., Fouchier, R.A., Osterhaus, A.D., and Rimmelzwaan, G.F. (2005). Functional constraints of influenza A virus epitopes limit escape from cytotoxic T lymphocytes. J. Virol. 79, 11239–11246.
23. Wu, N.C., Thompson, A.J., Lee, J.M., Su, W., Arlian, B.M., Xie, J., Lerner, R.A., Yen, H.L., Bloom, J.D., and Wilson, I.A. (2020). Different genetic barriers for resistance to HA stem antibodies in influenza H3 and H1 viruses. Science 368, 1335–1340.
24. Gostic, K.M., Ambrose, M., Worobey, M., and Lloyd-Smith, J.O. (2016). Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting. Science 354, 752–756.
25. Sridhar, S. (2016). Heterobutycipic T-Cell Immunity to Influenza in Humans: Challenges for Universal T-Cell Influenza Vaccines. Front. Immunol. 7, 195.
26. Clemens, E.B., van de Sandt, C., Wong, S.S., Wakim, L.M., and Valkenburg, S.A. (2018). Harnessing the Power of T Cells: The Promising Hope for a Universal Influenza Vaccine. Vaccines (Basel) 6, e18.
27. Chattopadhyay, S., Chen, J.Y., Chen, H.W., and Hu, C.J. (2017). Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation. Nanotheranostics 1, 244–260.
28. Irvine, D.J., Swartz, M.A., and Szeto, G.L. (2013). Engineering synthetic vaccines using cues from natural immunity. Nat. Mater. 12, 978–990.
29. Fang, R.H., and Zhang, L. (2016). Nanoparticle-Based Modulation of the Immune System. Annu. Rev. Chem. Biomol. Eng. 7, 305–326.
30. Deng, L., Chang, T.Z., Wang, Y., Li, S., Wang, S., Matsuyama, S., Wu, Y., Comans, R.W., Li, J.D., Prausnitz, M.R., et al. (2018). Heterobutycipic influenza protection elicited by double-layered polyoctanopeptide nanoparticles in mice. Proc. Natl. Acad. Sci. USA 115, E7558–E7567.
31. Deng, L., Mohtan, T., Chang, T.Z., Gonzalez, G.X., Wang, Y., Kwon, Y.M., Kang, S.M., Comans, R.W., Champson, J.A., and Wang, B.Z. (2018). Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses. Nat. Commun. 9, 359.
32. Lin, L.-C.-W., Huang, C.-Y., Yao, B.-Y., Lin, J.-C., Agrawal, A., Algaiisi, A., Peng, B.-H., Liu, Y.-H., Huang, P.-H., Juang, R.-H., et al. (2019). Viromimetic STING agonist-loaded hollow polymeric nanoparticles for safe and effective vaccination against Middle East respiratory syndrome coronavirus. Adv. Funct. Mater. 29, 1807616.
33. Lin, S.Y., Yao, B.-Y., Hu, C.J., and Chen, H.W. (2020). Induction of Robust Immune Responses by Cpg-ODN-Loaded Hollow Polymeric Nanoparticles for Antiviral and Vaccine Applications in Chickens. Int. J. Nanomedicine 15, 3303–3318.
34. Chattopadhyay, S., Liu, Y.H., Fang, Z.S., Lin, C.L., Lin, J.C., Yao, B.-Y., and Hu, C.J. (2020). Synthetic Immunogenic Cell Death Mediated by Intracellular Delivery of STING Agonist Nanoshells Enhances Anticancer Chemo-immunotherapy. Nano Lett. 20, 2246–2256.
35. Chen, Z., and John Wherry, E. (2020). T cell responses in patients with COVID-19. Nat. Rev. Immunol. 20, 529–536.
36. Braut, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey, M., Kruse, B., Fauchere, F., et al. (2020). SARS-CoV-2 reactive T cells in healthy donors and patients with COVID-19. Nature 587, 270–274.
37. Le Bert, N., Tan, A.T., Kunasegaran, K., Tham, C.Y.L., Hafezi, M., Chia, A., Chng, M.H.Y., Lin, M., Tan, N., Linster, M., et al. (2020). SARS-CoV-2 specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584, 457–462.
38. Rosendahl Huber, S., van Beek, J., de Jonge, J., Luyties, W., and van Baarle, D. (2014). T cell responses to viral infections - opportunities for Peptide vaccination. Front. Immunol. 5, 171.
the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J. Exp. Med. 198, 1023–1034.

56. Li, A.V., Moon, J.J., Abraham, W., Suh, H.Y., Elkhader, J., Seidman, M.A., Yen, M.M., Im, E.-J.J., Foley, M.H., Barouch, D.H., et al. (2013). Generation of Effector Memory T Cell-Based Mucosal and Systemic Immunity with Pulmonary Nanoparticle Vaccination. Sci. Transl. Med 5, 204ra130.

57. Stary, G., Olive, A., Radovic-Moreno, A.F., Gondek, D., Alvarez, D., Basto, P.A., Perro, M., Vrbanac, V.D., Tager, A.M., Shi, J., et al. (2015). A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells. Science 348, aaa8205.

58. Uddback, I.E., Pedersen, L.M., Pedersen, S.R., Steffensen, M.A., Holst, P.J., Thomsen, A.R., and Christensen, J.P. (2016). Combined local and systemic immunization is essential for durable T-cell mediated heterosubtypic immunity against influenza A virus. Sci. Rep. 6, 20137.

59. Purcell, A.W., Ramarathinam, S.H., and Ternette, N. (2019). Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics. Nat. Protoc. 14, 1687–1707.

60. Vita, R., Mahajan, S., Overton, J.A., Dhanda, S.K., Martini, S., Cantrell, J.R., Wheeler, D.K., Sette, A., and Peters, B. (2019). The Immune Epitope Database (IEDB): 2018 update. Nucleic Acids Res. 47 (D1), D339–D343.

61. Li, S., Liu, C., Klimov, A., Subbarao, K., Perdue, M.L., Mo, D., Ji, Y., Woods, L., Hietala, S., and Bryant, M. (1999). Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. J. Infect. Dis. 179, 1132–1138.